• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial ADULT CARDIAC
CONCLUSIONS Patients with diabetes had greater risk of major cardiovascular events long-term after off-pump CABG than after on-pump CABG.
Source: European Journal of Cardio-Thoracic Surgery - January 13, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Singh, A., Schaff, H. V., Mori Brooks, M., Hlatky, M. A., Wisniewski, S. R., Frye, R. L., Sako, E. Y., on behalf of the BARI 2D Study Group Tags: Electrophysiology - arrhythmias, Molecular biology ADULT CARDIAC Source Type: research

Long-Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting Cardiovascular Surgery
Conclusions The long-term risk for stroke after coronary artery bypass grafting was increased in patients with type 1 and type 2 diabetes, compared to patients with no diabetes.
Source: JAHA:Journal of the American Heart Association - November 9, 2015 Category: Cardiology Authors: Nystrom, T., Holzmann, M. J., Sartipy, U. Tags: Cardiovascular Surgery Source Type: research

Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease Coronary Artery Disease
Conclusions— In patients with diabetes mellitus and multivessel disease, EES was associated with lower upfront risk of death and stroke when compared with coronary artery bypass graft surgery. However, at long-term, EES was associated with similar risk of death, a higher risk of MI (in those with incomplete revascularization), and repeat revascularization but a lower risk of stroke.
Source: Circulation: Cardiovascular Interventions - July 8, 2015 Category: Cardiology Authors: Bangalore, S., Guo, Y., Samadashvili, Z., Blecker, S., Xu, J., Hannan, E. L. Tags: Type 2 diabetes, Catheter-based coronary interventions: stents, CV surgery: coronary artery disease, Chronic ischemic heart disease Source Type: research

Abstract 263: Incidence of Recurrent Cardiovascular Events and Disease Burden Among High-Risk Patients with Hyperlipidemia Session Title: Poster Session II
Conclusions: CV event-related risk and long-term costs are significantly greater among high-risk patients with shorter time intervals between recurrent CV events. Underutilization of LLTs in these patients highlights the need for improving clinical management and treatment options for these patients.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Punekar, R. S., Fox, K. M., Richhariya, A., Fisher, M. D., Gandra, S. R., Cziraky, M. J., Toth, P. P. Tags: Session Title: Poster Session II Source Type: research

Surgical revascularization for patients with diabetes: Do all roads lead to Rome?
The BARI 2D trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial)1 randomly allocated patients with type 2 diabetes and stable coronary artery disease (CAD) and evidence of myocardial ischemia to undergo, at the discretion of the treating physician, either early revascularization with a percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) with optimal medical therapy (OMT), or OMT alone. Patients in the OMT group were also randomly assigned to insulin-sensitizing strategy (metformin and thiazolidinedione) or an insulin-providing strategy (insulin or secretagogue.) The 5-year follo...
Source: The Journal of Thoracic and Cardiovascular Surgery - August 28, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Tomas A. Salerno Tags: Editorial commentary Source Type: research

Prognostic implications of DPP‐4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting – results of the 1 year follow‐up of the prospective DiaRegis registry
ConclusionsThe present results confirm prior randomised controlled trial results in patients with type 2 diabetes from real world clinical practice demonstrating that DPP4‐I on top of prior metformin monotherapy result in similar HbA1c reductions within 12 months but a significant reduction in hypoglycaemia compared with sulfonylurea added to metformin. The reduction in vascular events observed has to be verified in larger cohorts.
Source: International Journal of Clinical Practice - August 28, 2013 Category: Internal Medicine Authors: A. K. Gitt, P. Bramlage, C. Binz, M. Krekler, E. Deeg, D. Tschöpe Tags: Original Paper Source Type: research

Pages: 1  2  3  4